Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Papers of the Week
Annotation


Vieira SI, Rebelo S, Esselmann H, Wiltfang J, Lah J, Lane R, Small SA, Gandy S, da Cruz E Silva EF, da Cruz E Silva OA. Retrieval of the Alzheimer's amyloid precursor protein from the endosome to the TGN is S655 phosphorylation state-dependent and retromer-mediated. Mol Neurodegener. 2010;5:40. PubMed Abstract

Comments on Paper and Primary News
  Comment by:  Samuel Gandy
Submitted 13 October 2010  |  Permalink Posted 13 October 2010

The narrative on APP phosphorylation began in 1988 with the discovery that threonine 654 and serine 655 were potentially phospho-acceptor sites for protein kinase C (PKC) and Ca2+/calmodulin-dependent protein kinase II (CaMKII) (Gandy et al., 1988). Based on that lead, the effects of PKC activation on APP metabolism were discovered. The impact of acute PKC activation was stimulation of α-secretase cleavage and release of sAPPα (Buxbaum et al., 1990; Caporaso et al., 1992). Mutagenesis of the APP cytoplasmic tail showed that direct APP phosphorylation did not play an obvious role in phosphorylation-stimulated α-secretase cleavage (da Cruz e Silva et al., 1993), but both phosphorylation and α-secretase cleavage of APP have continued to receive substantial attention over the ensuing 17 years. “Regulated α-secretase cleavage” provided the first mechanism for decreasing Aβ generation (  Read more

  Comment by:  Vanessa Schmidt, Thomas Willnow
Submitted 18 October 2010  |  Permalink Posted 18 October 2010

The study by Vieira and colleagues investigates a potential role for APP phosphorylation in regulation of retrograde transport from endosomes to the trans-Golgi network (TGN). Recently, this trafficking route received particular attention because of the association of amyloidogenic processing with late endosomal compartments.

Several components of the retrograde sorting pathways, including the adaptor complex retromer and the sorting receptor SORLA/SORL1, have been implicated in intracellular transport and processing of APP, and in AD-related pathologies in animal models and in humans. Taken together, these findings argue that altered trafficking of APP between endosomes (where APP processing occurs) and the Golgi may be a molecular mechanism underlying enhanced amyloidogenic processing in sporadic AD.

Now, this work by Vieira et al. identifies interesting new details of the regulatory processes that may control transport of APP between endosomes and the TGN. Using immunofluorescence microscopy, the authors investigate the intracellular trafficking of APP-GFP fusion...  Read more

  Submit a Comment on this Paper
Cast your vote and/or make a comment on this paper. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend this paper

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
 
 

REAGENTS/MATERIAL:
Primary monoclonal antibodies used were: clone 22C11 (Chemicon) against the APP ectodomain, mouse anti-GFP (JL-8) (Clontech) for detection of the GFP moiety in APP-GFP proteins, the 1E8 monoclonal antibody (Nanotools, Germany) for Abeta detection, and two anti-APP C-terminal antibodies (rabbit anti-APP C-terminal, Zymed; rabbit anti-APP C-terminal 369 antibody).
Co-localization studies were carried out with anti-Rab5 (early endosomal marker) (StressGen Enzo Life Sciences) and anti-Rab7 (late-endosomal marker) (CytoSignal), polyclonal rabbit antibodies, polyclonal goat anti-clathrin (ICN Immunobiologicals), monoclonal mouse anti-cathepsin D lysosomal marker (49) (BD Biosciences), and polyclonal goat anti-VPS35 C-20 (Santa Cruz Biotechnology).
Immunoprecitipation and detection of SorLa was carried out using monoclonal mouse anti-N-terminal SorLA (48/LR11) (BD transduction labs) or anti-SorLA C-terminal antibody raised by Dr. James Lah; an anti-GFP antibody (Sigma) was used in the IP controls.

Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad